BR112022005045A2 - DOSAGE FORM, USE AND KIT OF(S)-BUPROPION THAT IS AT LEAST 95% ENANTIOMERICALLY PURE - Google Patents

DOSAGE FORM, USE AND KIT OF(S)-BUPROPION THAT IS AT LEAST 95% ENANTIOMERICALLY PURE

Info

Publication number
BR112022005045A2
BR112022005045A2 BR112022005045A BR112022005045A BR112022005045A2 BR 112022005045 A2 BR112022005045 A2 BR 112022005045A2 BR 112022005045 A BR112022005045 A BR 112022005045A BR 112022005045 A BR112022005045 A BR 112022005045A BR 112022005045 A2 BR112022005045 A2 BR 112022005045A2
Authority
BR
Brazil
Prior art keywords
bupropion
kit
dosage form
enantiomerically pure
dosage forms
Prior art date
Application number
BR112022005045A
Other languages
Portuguese (pt)
Inventor
Tabuteau Herriot
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/052210 external-priority patent/WO2020061486A2/en
Priority claimed from US16/830,637 external-priority patent/US20200222339A1/en
Priority claimed from US16/907,691 external-priority patent/US11433035B2/en
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of BR112022005045A2 publication Critical patent/BR112022005045A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta invenção está relacionada a formas de dosagem contendo uma bupropiona enantiomericamente enriquecida ou pura, tal como excesso enantiomérico de (S)-bupropiona, (S)-bupropiona enantiomericamente enriquecida, ou (S)-bupropiona enantiomericamente pura e métodos de uso dessas formas de dosagem. Estas formas de dosagem podem ser administradas a seres humanos em quantidade reduzida em comparação com a quantidade de bupropiona racêmica que seria administrada na mesma situação.This invention relates to dosage forms containing an enantiomerically enriched or pure bupropion, such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion, and methods of using such dosage forms. dosage. These dosage forms can be administered to humans in a reduced amount compared to the amount of racemic bupropion that would be administered in the same situation.

BR112022005045A 2019-09-20 2020-08-18 DOSAGE FORM, USE AND KIT OF(S)-BUPROPION THAT IS AT LEAST 95% ENANTIOMERICALLY PURE BR112022005045A2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/US2019/052210 WO2020061486A2 (en) 2018-09-20 2019-09-20 Dosage forms and methods for enantiomerically enriched or pure bupropion
US202062971174P 2020-02-06 2020-02-06
US202062978626P 2020-02-19 2020-02-19
US202062992060P 2020-03-19 2020-03-19
US16/830,637 US20200222339A1 (en) 2018-09-20 2020-03-26 Dosage forms and methods for enantiomerically enriched or pure bupropion
US16/907,691 US11433035B2 (en) 2018-09-20 2020-06-22 Dosage forms and methods for enantiomerically enriched or pure bupropion
PCT/US2020/046755 WO2021055124A1 (en) 2019-09-20 2020-08-18 Dosage forms and methods for enantiomerically enriched or pure bupropion

Publications (1)

Publication Number Publication Date
BR112022005045A2 true BR112022005045A2 (en) 2022-07-05

Family

ID=74884634

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005045A BR112022005045A2 (en) 2019-09-20 2020-08-18 DOSAGE FORM, USE AND KIT OF(S)-BUPROPION THAT IS AT LEAST 95% ENANTIOMERICALLY PURE

Country Status (14)

Country Link
EP (1) EP4031121A4 (en)
JP (2) JP2022549192A (en)
KR (1) KR20220066930A (en)
CN (1) CN114423417A (en)
AU (2) AU2020349419B2 (en)
BR (1) BR112022005045A2 (en)
CA (1) CA3154718A1 (en)
CO (1) CO2022003126A2 (en)
CR (1) CR20220119A (en)
EC (1) ECSP22030119A (en)
IL (1) IL291514A (en)
MX (1) MX2022003346A (en)
PE (1) PE20221314A1 (en)
WO (1) WO2021055124A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1051166A1 (en) * 1998-01-29 2000-11-15 Sepracor, Inc. Pharmaceutical uses of optically pure (+) -bupropion
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
US20190216800A1 (en) * 2013-11-05 2019-07-18 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
MX2013014166A (en) * 2013-12-03 2015-06-10 Inst De Investigacion En Quimica Aplic S A De C V Active enantiomers and the salts thereof for treating obesity.
US9732031B2 (en) * 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
MX2020008704A (en) * 2018-02-23 2020-12-07 Axsome Therapeutics Inc Dosage forms and methods for enantiomerically enriched or pure bupropion.

Also Published As

Publication number Publication date
JP2024059812A (en) 2024-05-01
KR20220066930A (en) 2022-05-24
EP4031121A1 (en) 2022-07-27
CO2022003126A2 (en) 2022-04-19
CR20220119A (en) 2022-06-22
AU2020349419B2 (en) 2023-11-02
CN114423417A (en) 2022-04-29
IL291514A (en) 2022-05-01
ECSP22030119A (en) 2022-05-31
MX2022003346A (en) 2022-04-11
AU2024200081A1 (en) 2024-01-25
PE20221314A1 (en) 2022-09-07
EP4031121A4 (en) 2022-11-30
CA3154718A1 (en) 2021-03-25
AU2020349419A1 (en) 2022-03-24
JP2022549192A (en) 2022-11-24
WO2021055124A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
MY196526A (en) Non-Racemic Beta-Hydroxybutyrate Compounds and Compositions Enriched With The R-Enantiomer And Methods Of Use
MX2020000734A (en) S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same.
MX2020006386A (en) Non-racemic beta-hydroxybutyrate compounds and compositions enriched with s-enantiomer and methods of use.
WO2020061486A3 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
CO2020010342A2 (en) Arni compositions of 17 β -hydroxysteroid dehydrogenases type 13 (hsd17b13) and methods of use thereof
CL2011001529A1 (en) Use of a modulator or s1p receptor agonist derived from 2-amino-propan-1,3-diol or 2-amino-propanol to treat a long chronic disease in a subject, so as to achieve a daily decrease in heart rate of 2 beats / minutes or less; and kit that understands it.
CL2020002512A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors.
CL2008001721A1 (en) Compounds derived from 17-beta-cyano-18 alpha-homo-19-nor-androst-4-eno; presenting gestagenic and antimineralcorticoid activity; pharmaceutical composition; and use in the treatment of pre-peri-and postmenopausal disorders and premenstrual disorders.
CL2008003593A1 (en) Isoxazolo-pyridazine derived compounds; preparation procedure; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cognitive disorders such as Alzheimer's
UY29796A1 (en) NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS
BR112016021034A8 (en) pharmaceutical composition, use thereof and kit
BRPI0507895A (en) composition for the treatment of chronic venous insufficiency, comprising an extract of red vine leaves and an anti-inflammatory agent
AR115585A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF FAT INFILTRATION IN MUSCLE
CL2019002218A1 (en) Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease.
CO2022007005A2 (en) Substituted aminoquinolones as dgk alpha inhibitors for immune activation
BR112021024255A2 (en) Kits comprising unit dose oral treatment compositions
UA84697C2 (en) Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament
CL2011002650A1 (en) Composition comprising n- (4- (2-furyl) -5- (tetrahydropyran-4-ylcarbonyl) thiazol-2-yl) -2-methylpyridine-5-carboxamide and l-dopa; use of the compound for the treatment of a secondary movement disorder of l-dopa therapy; use of the compound and l-dopa and / or for the treatment and / or prophylaxis of parkinson's disease.
CL2020001349A1 (en) Compounds, composition and use of the same as modulators of the expression of pcsk9. (divisional request 201902574)
NI202000056A (en) DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION
MX2021002754A (en) Treatment of autism and autism spectrum disorders with biotin compositions.
PE20211199A1 (en) USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY
MX2021007142A (en) Organic compounds.
BR112022005045A2 (en) DOSAGE FORM, USE AND KIT OF(S)-BUPROPION THAT IS AT LEAST 95% ENANTIOMERICALLY PURE
BR112015023772A2 (en) stable dental varnish compositions and method of manufacture and use